Skip to main content
Log in

Polymorphism of debrisoquine oxidation in New Zealand Caucasians

  • Short Communications
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

References

  1. Kalow W (1982) Ethnic differences in drug metabolism. Clin Pharmacokinet 7: 373–400

    Google Scholar 

  2. Bertilsson L, Mellstrom B, Sawe J, Sjoqvist F (1981) Pharmacogenetic aspects of the metabolism of tricyclic antidepressants. In: Langer SZ, Takahashi R, Segawa T, Briley M (ed) New vistas in depression. Pergamon, Oxford

    Google Scholar 

  3. Kupfer A, Preisig R (1984) Pharmacogenetics of mephenytoin: a new drug hydroxylation polymorphism in man. Eur J Clin Pharmacol 26: 753–759

    Google Scholar 

  4. Alvan G, Bechtel P, Iselius L, Gundert-Remy U (1990) Hydroxylation polymorphisms of debrisoquine and mephenytoin in European populations. Eur J Clin Pharmacol 39: 533–537

    Google Scholar 

  5. Islam SI, Idle JR, Smith RL (1980) The polymorphic 4-hydroxylation of debrisoquine in a Saudi arab population. Xenobiotica 10: 819–825

    Google Scholar 

  6. Mahgoub A, Idle JR, Smith RL (1979) A population and family study of the defective alicyclic hydroxylation of debrisoquine among Egyptians. Xenobiotica 9: 51–56

    Google Scholar 

  7. Nakamura K, Goto F, Ray WA, McAllister CB, Jacqz E, Wilkinson GR, Branch RA (1985) Inter-ethnic differences in genetic polymorphism of debrisoquine and mephenytoin hydroxylation between Japanese and Caucasian populations. Clin Pharmacol Ther 38: 402–408

    Google Scholar 

  8. Lee EJD, Yeoh PN, Gong NH (1988) Oxidation phenotyping in Chinese and Malay populations. Clin Exp Pharmacol Physiol 15: 889–891

    Google Scholar 

  9. Lou YC, Ying L, Bertilsson L, Sjoqvist F (1987) Low frequency of slow debrisoquine hydroxylation in a native Chinese population. Lancet II: 852–853

    Google Scholar 

  10. Wanwimolruk S, Patamasucon P, Lee EJD (1990) Evidence for the polymorphic oxidation of debrisoquine in the Thai population. Br J Clin Pharmacol 29: 244–247

    Google Scholar 

  11. Peart GF, Boutagy J, Shenfield GM (1986) Debrisoquine oxidation in an Australian population. Br J Clin Pharmacol 21: 465–471

    Google Scholar 

  12. Wanwimolruk S, Ferry DG (1990) Rapid high-performance liquid chromatographic method for the analysis of debrisoquine and 4-hydroxydebrisoquine in urine without derivatization. J Liq Chromatogr 13: 961–968

    Google Scholar 

  13. Price-Evans DA, Mahgoub A, Sloan TP, Idle JR (1980) A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet 17: 102–105

    Google Scholar 

  14. Brosen K, Otton SV, Gram LF (1985) Sparteine oxidation polymorphism in Denmark. Acta Pharmacol Toxicol 57: 357–360

    Google Scholar 

  15. Szorady I, Santa A (1987) Drug hydroxylator phenotype in Hungary. Eur J Clin Pharmacol 32: 325

    Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wanwimolruk, S., Denton, J.R., Ferry, D.G. et al. Polymorphism of debrisoquine oxidation in New Zealand Caucasians. Eur J Clin Pharmacol 42, 349–350 (1992). https://doi.org/10.1007/BF00266364

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00266364

Key words

Navigation